Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 5:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 390 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Glaucoma, Pigmentary Clear all
Completed Phase 2 Interventional

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

NCT07168902
View directory record Official record
Conditions
Glaucoma
Interventions
BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Glendale, California • Newport Beach, California • Pasadena, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 6, 2026, 5:17 PM EDT
Terminated No phase listed Observational

Effects of Selective Laser Trabeculoplasty

NCT00986141
View directory record Official record
Conditions
Glaucoma
Interventions
Surgery, Selective Laser Trabeculoplasty
Procedure
Lead sponsor
University of Kentucky
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 6, 2026, 5:17 PM EDT
Completed Phase 1 Interventional Results available

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

NCT03131167
View directory record Official record
Conditions
Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Interventions
SHP639 (n=60), Placebo Comparator (n=24)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 6, 2026, 5:17 PM EDT
Not listed Not applicable Interventional

iStent Inject New Enrollment Post-Approval Study

NCT04624698
View directory record Official record
Conditions
Glaucoma, Open-Angle, Glaucoma
Interventions
iStent Inject Implantation
Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
22 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Phoenix, Arizona • Torrance, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 6, 2026, 5:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bimatoprost Ocular Insert Pharmacokinetic Study

NCT02444767
View directory record Official record
Conditions
Healthy Volunteers
Interventions
13mg Bimatoprost Ocular Insert
Drug
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Oct 6, 2026, 5:17 PM EDT
Completed Phase 3 Interventional

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

NCT03850782
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost (SR)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
38
States / cities
Sun City, Arizona • Huntington Beach, California • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 6, 2026, 5:17 PM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy

NCT02984813
View directory record Official record
Conditions
Open-angle Glaucoma, Diabetic Retinopathy
Interventions
GlaucoHealth, GlaucoSelect, Placebo
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 6, 2026, 5:17 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Efficacy of Selective Laser Trabeculoplasty

NCT00347893
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension, Pseudo-Exfoliative Glaucoma, Pigment Dispersion Glaucoma
Interventions
Selective laser trabeculoplasty
Procedure
Lead sponsor
Glaucoma Research & Education Group
Other
Eligibility
0 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 4, 2006 · Synced Oct 6, 2026, 5:17 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07075718
View directory record Official record
Conditions
Glaucoma
Interventions
Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, Placebo eye drops
Drug · Procedure · Other
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Grand Junction, Colorado • Oklahoma City, Oklahoma • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 6, 2026, 5:17 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Hydrus Microstent as a Quality of Life Consideration

NCT05955118
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Hydrus Microstent
Device
Lead sponsor
InSight Vision Center Medical Group, Inc
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 6, 2026, 5:17 PM EDT
Recruiting No phase listed Observational

DSLT for Reducing Medication in Glaucoma

NCT07390890
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
Voyager DSLT
Device
Lead sponsor
The Eye Institute of West Florida
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Largo, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 6, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Autoimmune Dysregulation in Pigmentary Glaucoma

NCT00280345
View directory record Official record
Conditions
Pigmentary Glaucoma, Primary Open Angle Glaucoma, Cataract
Interventions
Trabeculectomy, Trabeculectomy and cataract surgery, Cataract surgery
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 6, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma

NCT01670266
View directory record Official record
Conditions
Ocular Hypertension (OHT), Mild Open Angle-glaucoma (OAG)
Interventions
ONO-9054, Placebo
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
3
States / cities
Costa Mesa, California • Newport Beach, California • Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 6, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

Study of Exchange of Travoprost Intraocular Implant

NCT04615403
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Travoprost
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Hemet, California • Petaluma, California • Fort Collins, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 6, 2026, 5:17 PM EDT
Withdrawn No phase listed Observational

24-hour IOP Fluctuation Profile Recorded With SENSIMED Triggerfish in Primary Open-angle Glaucoma (POAG) Patients After Cataract Surgery

NCT01495299
View directory record Official record
Conditions
Glaucoma
Interventions
Phacoemulsification with implantation of intraocular lens (CE-IOL) SENSIMED Triggerfish
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 6, 2026, 5:17 PM EDT
Completed Phase 2 Interventional

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

NCT00069719
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Glaucoma therapy
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Multiple Locations Throughout the US Sponsored by Alcon of, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 6, 2026, 5:17 PM EDT
Completed Phase 2 Interventional

Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma

NCT00845299
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprost punctal plug, artificial tears preserved with Benzalkonium Chloride
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 6, 2026, 5:17 PM EDT
Completed Phase 3 Interventional

AqueSys Microfistula Implant in Refractory Glaucoma

NCT01640756
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open-Angle
Interventions
AqueSys Microfistula Implant
Device
Lead sponsor
AqueSys, Inc.
Industry
Eligibility
45 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
14
States / cities
Fayetteville, Arkansas • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 6, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Results available

Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension

NCT04910100
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Nebivolol Ophthalmic Suspension 1 Percent, Nebivolol Ophthalmic Suspension 0.5 Percent, Timolol Ophthalmic Suspension 0.5 Percent, Timolol Ophthalmic Solution 0.5 Percent
Drug
Lead sponsor
Betaliq, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 6, 2026, 5:17 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study Comparing Two Models of a Travoprost Intraocular Implant

NCT03868124
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
G2-TR intraocular implant containing travoprost, Sham surgery + active-comparator eye drops
Combination Product · Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 6, 2026, 5:17 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Combined Phacoemulsification With iStent Inject W Versus Hydrus for Mild to Moderate Open Angle Glaucoma

NCT05583591
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Combined cataract surgery with Hydrus microstent, Combined cataract surgery with iStent Inject W
Device
Lead sponsor
Diablo Eye Associates
Industry
Eligibility
60 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 6, 2026, 5:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Will Listening to Music Make it Easier to Take a Visual Field Test?

NCT01027039
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Oct 6, 2026, 5:17 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT

NCT01895972
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprostene bunod
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
20 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 6, 2026, 5:17 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Safety and Efficacy of PDP-716

NCT03450629
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Brimonidine Tartrate Ophthalmic Suspension, Brimonidine Tartrate Ophthalmic Solution
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
2 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
47
States / cities
Chandler, Arizona • Prescott, Arizona • Sun City, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 6, 2026, 5:17 PM EDT